Abstract
The administration of atracurium to humans has been reported to produce little cardiovascular effects in clinical doses. The cardiovascular effect, histamine-releasing and catecholamine releasing effects of intravenous injection of atracurium 0.6 and 1.2 mg·kg−1 were studied in man, and also the cardiovascular and catecholamine releasing effects of laudanosine which is a metabolite of atracurium by Hofmann degeneration, were studied in dogs. The increase in human plasma concentration of histamine, hypotension and tachycardia were found with the dose of atracurium 1.2 mg·kg−1. The intravenous administration of laudanosine 10 μg·kg−1 to dogs produced minimal epinephrine, norepinephrine releases and cardiovascular changes.
Similar content being viewed by others
References
Huges R, Chapple DJ: The pharmacology of atracurium: A new competitive neuromuscular blocking agent. Br J Anesth 53:31–44, 1981
Basta SJ, Sunder N, Savarese JJ: Clinical pharmacology of atracurium (BW33A): A new neuromuscular blocking agent. Anesth Analg 61:169–170, 1982
Payne JP, Huges R: Evaluation of atracurium in anesthetized man. Br J Anaesth 53:45–54, 1981
Basta SJ, Savarese J J, Ali HH: Histamine-releasing potencies of atrcurium, dimethyl tubocurarine and tubocurarine. Br J Anaesh 55:105S-106S, 1983
Hennis PJ, Fahey MR, Canfell PC: Pharmacology of laudanosine in dogs. Anesthesiology 65:56–60, 1986
Nagashima H, Visi ES, Kobayashi O: Atracurium and laudanosine increase3H-norepinephrine release from guinea pig atrium. Anesthesiology 65:A413, 1986
Beaven MA, Robinson-White A, Roderick NB: The demonstration of histamine release in clinical conditions: A review of past and present assay procedures. Kli Wockenschr 60:873–881, 1982
Fukushima K, Aoki T, Nagashima H: Plasma histamine levels following the intravenous administration of atracurium and vecuronium in man. 9th World Congress of Anesthesiologists, Washington, DC (Abstruct AO520), 1988
Kobayashi O, Nagashima H, Duncalf D, Chaudhry lA, Harsing LG Jr, Foldes FF, Goldiner PL, Visi ES: Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from arterial sympathetic nerve by inhibiting prejunctional muscarinic receptors. J Auton N Syst 18:55–60, 1987
Kinjo M, Nagashima H, Visi S: Effect of atracurium and laudanosine on the release of3H-noradrenaline. Br. J Anaesth 62:683–690, 1989
Yate PM, Arnold RW, Flynn PJ, Weatherley BC, Simmonds RJ, Dopson T: Atracurium infusions in the intensive care unit including measurement of plasma laudanosine. Anesthesiology 63:A313, 1985
Author information
Authors and Affiliations
About this article
Cite this article
Fukushima, K., Aoki, T., Watanabe, K. et al. The cardiovascular effects of atracurium and it's metabolite. J Anesth 4, 45–50 (1990). https://doi.org/10.1007/s0054000040045
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s0054000040045